The profitability of the API sector has gradually recovered, and enterprises have actively promoted industrial upgrading

【Pharmaceutical Network Market Analysis】 With the continuous change of human disease spectrum, the increasing total population, the increasing aging degree of various countries, the acceleration of urbanization, the enhancement of people's awareness of health care and the further improvement of the medical insurance system, the market size of the global pharmaceutical industry is increasing
year by year.
According to the data, the compound annual growth rate of the global pharmaceutical industry market size will reach 5.
67%
from 2020 to 2025.
The API market follows the overall expansion of the pharmaceutical industry, and the market size is also growing
year by year.
Analysts pointed out that in recent years, the number of original drugs has been increasing, the number of generic drugs has risen rapidly, and the demand for corresponding APIs has also increased greatly, and it is expected that the global API industry will maintain stable growth and a good development trend
.
According to the data, from 2019 to 2024, the global API market size will grow
at a compound growth rate of 6.
1%.
According to the statistics of the Price Supervision and Competition Bureau of the National Development and Reform Commission, China can produce more than 1,500 kinds of APIs, with a total output of one million tons and an export volume of more than 60%, which has become a large-scale API producer and export country
.
In this regard, some insiders said that the direction of pharmaceutical advanced manufacturing continues to pay attention to the API sector and the upstream supply chain
of pharmaceuticals.
The profitability of the API sector has gradually recovered, and the industrial upgrading + industrial extension has driven the continuous and steady development
of the sector.
It is understood that in the API market, domestic enterprises continue to deepen the field of characteristic APIs to promote the development of
the industry.
For example, Aurisco has been focusing on the R&D, production and sales
of characteristic complex APIs and pharmaceutical intermediates for many years.
After more than 20 years of deep cultivation, it has established a product chain
covering six major fields, including respiratory, cardiovascular, anti-infective, nervous system, anti-tumor and women's health.
At present, Aurisco is one of the few companies in the world that can commercially produce drogesterone APIs, which has strong scarcity
.
Yangzhou Aurisco obtained the European CEP certificate on November 7, 2022, which will help the company to open the door to regulatory markets such as Europe for dydrogesterone
APIs.
The data shows that the existing products of Aurisco include 18 API products and 15 intermediate products; There are 19 API products under development, of which 8 products have been in the pilot stage, and the treatment areas cover women's health drugs, anti-infective drugs, anti-tumor drugs, hypoglycemic drugs and other categories
.
With the continuous advancement of follow-up API research and development, the company will enhance its long-term competitiveness
.
It is reported that Xintiandi Pharmaceutical conforms to the new trend of pharmaceutical industry development, takes the shortage type, is in the product introduction period and rapid volume period of API varieties as the development goal, relying on its own advantages in chiral drug preparation technology and green preparation process, etc.
, to actively expand the downstream market
。 From the performance point of view, from 2019 to 2021, Xintiandi Pharmaceutical achieved operating income of 407 million yuan, 433 million yuan and 514 million yuan, respectively, with steady growth in its main business; The net profit attributable to the parent was 109 million yuan, 118 million yuan and 115 million yuan, which remained stable
.
In the first three quarters of 2022, Xintiandi Pharmaceutical achieved revenue of 448 million yuan, an increase of 37.
06% over the same period of the previous year; The net profit attributable to the parent was 89.
2921 million yuan, an increase of 16.
13%
over the same period of the previous year.
Analysts pointed out that Xintiandi Pharmaceutical expects that in the future, with the continuous optimization of the company's production process and the continuous approval of the products developed, the economic benefits brought by project construction will be gradually reflected
.
It is reported that as of the signing date of the new IPO letter of intent, the company's lidocaine hydrochloride API and naphazoline hydrochloride API have passed the evaluation of the Drug Evaluation Center of the State Medical Products Administration and completed the filing registration
.
In addition, 4 of the 18 APIs currently under research and development of Xintiandi Pharmaceutical have been submitted to the Center for Drug Evaluation of the State Medical Products Administration for registration, of which 1 variety has passed the on-site verification
of drug registration and production.
With the support of the national industrial policy, the status of the API industry in the industrial chain has steadily improved, and it is expected that China's API output and operating income will maintain continuous growth
.
It is expected that by 2025, the innovation and development of the API industry and the level of advanced manufacturing are expected to be further improved, and API companies will also usher in more opportunities
.
In addition, industry insiders said that with the promotion of quality control policies such as raw and auxiliary package association review and consistency evaluation, China's API industry will develop
in the direction of high quality, high added value and green environmental protection.